Loading...
Common arm comparative outcomes analysis of phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level results from JCOG 9511 and SWOG 0124
BACKGROUND: S0124 was a large North American phase III trial that failed to confirm a survival benefit for cisplatin/irinotecan over cisplatin/etoposide in patients with extensive stage small cell lung cancer (E-SCLC). These results were contrary to J9511, a phase III trial exclusively in Japanese p...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2994945/ https://ncbi.nlm.nih.gov/pubmed/20737417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25532 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|